Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Cellemedy Co. Ltd. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners and 3 distinct art units, indicating that each pending matter is situated in a separate examination context.
BALLARD, KIMBERLY is the busiest examiner, with 1 pending matter. Responses should be organized by application because the available record does not show a shared examiner or art-unit assignment.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BALLARD, KIMBERLY | 1 | 53.6% | +49.5% |
| WEN, SHARON X | 1 | 56.8% | +32.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18289179 | MUTATED FERRITIN PROTEIN | BALLARD, KIMBERLY | — |
| 18289152 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF LUNG CANCER | WEN, SHARON X | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18289179 | MUTATED FERRITIN PROTEIN | BALLARD, KIMBERLY | 1675 | §103DP | Non-Final OA | — | Pending | Nov 01, 2023 |
| 18289152 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF LUNG CANCER | WEN, SHARON X | 1641 | §103DP | Non-Final OA | — | Pending | Nov 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCellemedy Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Kimberly Ballard has the most, with 1 of Cellemedy Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
